Supplementary Figure S1 from Clinical Benefit of Avapritinib in &lt;i&gt;KIT-&lt;/i&gt;Mutant Gastrointestinal Stromal Tumors: A &lt;i&gt;Post Hoc&lt;/i&gt; Analysis of the Phase I NAVIGATOR and Phase I/II CS3007–001 Studies